Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa MART-1 TCR gene therapy in metastatic melanoma
NL-OMON47165Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2012
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in melanoma and intraocular melanoma, sponsored by Netherlands Cancer Institute. Primary endpoints: Safety of TCR treatment and Objective response rate. Started Sep 2012; status: active, not recruiting.
02
Conditions
melanomaintraocular melanoma
Beyond the preview
Go deeper on NL-OMON47165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47165.